Principal Investigator
Namrata Chandhok
Enrollment Status
Open
Clinical Trial ID
Institutional Protocol #
20231417
Clinical Trial Summary
A Phase 1, Open-label, Preliminary Pharmacokinetics (PK) and Safety Study of CLN-049 (An fms-like tyrosine kinase 3 [FLT3] x cluster of differentiation 3 [CD3] bispecific T cell engager) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Phase
Phase I
Funding Agency/Sponsor
Industrial
Disease
Leukemia
Contact Information
Phone Number
305-243-2647